Press release
Alzheimer's Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, Eisai Inc., T3D Therapeutics, Merck Sharp
Alzheimer's Disease therapies, such as AR1001, AGB101, AMX0035, IVL3003, BHV-8000, and others, are expected to boost the Alzheimer's Disease Market in the upcoming years.DelveInsight has launched a new report on "Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of Alzheimer's Disease, historical and forecasted epidemiology, as well as the Alzheimer's Disease market trends in Japan.
Discover about the Alzheimer's Disease market report @ https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Some of the key facts of the Alzheimer's Disease Market Report:
In 2024, Germany had the highest number of diagnosed prevalent Alzheimer's disease cases among the EU4 and the UK, accounting for about 30% of the total, with France following at 24%. DelveInsight experts project that the number of diagnosed cases across these regions will continue to rise in the coming years.
In the US, around 2.4 million men and 5 million women were affected by Alzheimer's disease in 2024, with these figures expected to grow by 2034.
DelveInsight's epidemiological model shows that in 2024, individuals aged 75-84 in the EU4 and the UK had the highest prevalence of Alzheimer's disease, totaling nearly 2 million cases. Meanwhile, those under 65 had the lowest number of cases, with approximately 130,000.
In Japan, there were around 2.5 million diagnosed prevalent cases of Alzheimer's disease-related agitation in 2024. This number is also anticipated to increase by 2034. Agitation, characterized by symptoms like restlessness, irritability, aggression, and anxiety, greatly impacts patient well-being and adds to caregiver burden.
In 2024, the United States represented approximately 44% of all diagnosed Alzheimer's disease cases across the 7MM, with an estimated 7 million individuals affected. DelveInsight projects this number will increase by 2034, highlighting the escalating impact of Alzheimer's disease on the U.S. healthcare system over the forecast period.
In June 2025, Hoffmann-La Roche initiated a study to assess the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of escalating intravenous (IV) doses of RO7126209 in individuals with prodromal or mild to moderate Alzheimer's disease who tested positive for amyloid via PET scan.
In June 2025, Annovis Bio Inc. launched a clinical trial to evaluate the effectiveness and safety of buntanetap (also known as Posiphen) in treating early-stage Alzheimer's disease in adults aged 55 to 85.
Eli Lilly and Company also conducted a study in June 2025 to determine whether its investigational treatment can delay or prevent the onset or progression of memory, cognitive, or functional impairments associated with Alzheimer's, compared to a placebo.
Meanwhile, UCB Biopharma SRL announced a trial to examine the impact of bepranemab versus placebo on changes in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) through Week 80 in participants with prodromal or mild Alzheimer's disease.
Key Alzheimer's Disease companies such as Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, Eisai Inc., T3D Therapeutics, Merck Sharp & Dohme, Shanghai Hengrui Pharmaceutical, NeuroSense Therapeutics, Pharmazz, Johnson & Johnson Innovative Medicine, NKGen Biotech, LEXEO Therapeutics, Inventage Lab, Neumora Therapeutics, Takeda, Perha Pharmaceuticals, Luye Pharma Group Ltd., Eli Lilly and Company, Prothena, Therabest Korea, Neurotez, TRIMTECH Therapeutics, Lexeo Therapeutics, and others are evaluating new drugs for Alzheimer's Disease to improve the treatment landscape.
Promising Alzheimer's Disease therapies include AR1001, AGB101, AMX0035, IVL3003, BHV-8000, and others.
Alzheimer's Disease Overview
Alzheimer's disease is a chronic and irreversible neurological condition that primarily affects memory, cognitive functions, and reasoning abilities. It is the most common cause of dementia, accounting for approximately 60-80% of all cases. While it typically develops in individuals in their mid-60s, early-onset cases, though rare, can appear in people in their 40s or 50s. The disease often begins with memory loss that disrupts everyday activities and gradually progresses to include confusion, difficulties with language, poor judgment, and behavioral changes. Although the precise cause of Alzheimer's remains unclear, it is linked to the buildup of amyloid beta plaques and tau tangles in the brain, which interfere with neuron communication and ultimately cause brain cell death. Advancing age and a family history of the disease are among the most significant risk factors.
Discover how the Alzheimer's Disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/alzheimers-disease-japan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Alzheimer's Disease Emerging Drugs
AR1001: AriBio Co., Ltd.
AGB101: AgeneBio
AMX0035: Amylyx Pharmaceuticals Inc
IVL3003: Inventage Lab., Inc.
BHV-8000: Biohaven Pharmaceuticals
Scope of the Alzheimer's Disease Market Report
Study Period: 2020-2034
Coverage: Japan
Key Alzheimer's Disease Companies: Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, Eisai Inc., T3D Therapeutics, Merck Sharp & Dohme, Shanghai Hengrui Pharmaceutical, NeuroSense Therapeutics, Pharmazz, Johnson & Johnson Innovative Medicine, NKGen Biotech, LEXEO Therapeutics, Inventage Lab, Neumora Therapeutics, Takeda, Perha Pharmaceuticals, Luye Pharma Group Ltd., Eli Lilly and Company, Prothena, Therabest Korea, Neurotez, TRIMTECH Therapeutics, Lexeo Therapeutics, and others
Alzheimer's Disease Therapies: AR1001, AGB101, AMX0035, IVL3003, BHV-8000, and others.
Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies
Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Alzheimer's Disease Market Access and Reimbursement
To know what's more in our Alzheimer's Disease report, visit https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key benefits of the Alzheimer's Disease Market Report:
Alzheimer's Disease market report covers a descriptive overview and comprehensive insight of the Alzheimer's Disease Epidemiology and Alzheimer's Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Alzheimer's Disease market report provides insights into the current and emerging therapies.
The Alzheimer's Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Alzheimer's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Alzheimer's Disease market.
Got queries? Click here to know more about the Alzheimer's Disease market Landscape https://www.delveinsight.com/sample-request/alzheimers-disease-japan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Alzheimer's Disease Patient Share (%) Overview at a Glance
5. Alzheimer's Disease Market Overview at a Glance
6. Alzheimer's Disease Background and Overview
7. Alzheimer's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Alzheimer's Disease
9. Alzheimer's Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Alzheimer's Disease Emerging Therapies
12. Alzheimer's Disease Market Outlook
13. Country-Wise Alzheimer's Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Alzheimer's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Alzheimer's Disease Market Outlook 2034 https://www.delveinsight.com/report-store/alzheimers-disease-japan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Related Reports:
Alzheimer's Disease Pipeline Insights, DelveInsight
"Alzheimer's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alzheimer's Disease market. A detailed picture of the Alzheimer's Disease pipeline landscape is provided, which includes the disease overview and Alzheimer's Disease treatment guidelines.
Contact Info:
Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Market: Epidemiology, Therapies, Companies, DelveInsight | Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuticals, Eisai Inc., T3D Therapeutics, Merck Sharp here
News-ID: 4074016 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
